CollPlant, a regenerative medicine company has announced that its corporate name has changed from "CollPlant Holdings Ltd." to "CollPlant Biotechnologies Ltd." effective on the opening of trading on June 21, 2019.

The Company's ADSs will continue trading on the Nasdaq Capital Market under the same ticker symbol "CLGN".

Yehiel Tal, CollPlant Biotechnologies CEO said, "This corporate rebranding, including our name change and new logo, effectively reflects the strategic shift in our business, and the high value opportunities we are pursuing in the field of regenerative medicine. Over the last two years, we have taken strategic actions transitioning the Company to focus on our medical aesthetics and 3D bioprinting platform technologies. The path ahead is clear and we look forward to providing further updates as we continue to execute upon our strategy."

CollPlant has made significant progress over the past two years in advancing its rhCollagen technology including signing a commercialization agreement for 3D bioprinted lung transplants with United Therapeutics (UTHR); establishing a new rhCollagen and BioInk production facility; launching a new HQ and R&D center and developing a new dermal filler product line for the medical aesthetics market.